Vimarsana
Biggest News Aggregation in the World

Buy Target News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Buy Target. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Buy Target Today - Breaking & Trending Today

Original-Research: Advanced Blockchain AG - from GBC AG Classification of GBC AG to Advanced Blockch - Vimarsana News

Original-Research: Advanced Blockchain AG - from GBC AG Classification of GBC AG to Advanced Blockch

Original-Research: Advanced Blockchain AG (von GBC AG): Buy

How analysts see ICICI Bank Q2 - Vimarsana News

How analysts see ICICI Bank Q2

Shares of ICICI Bank may outperform those of HDFC Bank in the near-term, analysts said recently, after the Sandeep Bakhshi-led private sector lender reported a strong set of numbers for the July to September quarter (Q2) of financial year 2023-24 (FY24). The result, they said, reiterated that ICICI Bank is maintaining a sustainable and prudent growth led by tech-driven initiatives as against HDFC Bank, which is facing merger related challenges. According to analysts at Prabhudas Lilladher, ICICI Bank is valued at par with HDFC Bank at 2.2x/1.9x on FY25/26E core adjusted book value (ABV) basis.

Source: rediff.com
Top 10 SMM Panel in India Market to Grow Online - Vimarsana News

Top 10 SMM Panel in India Market to Grow Online

Hey there! Social media has become an essential part of our daily lives, and its hard to imagine a world...

Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio (PACB) - Vimarsana News

Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio (PACB)

PacBio’s HiFi and SMRT sequencing technology continues to fuel growth. PACB believes itself to be on track to hit its full-year revenue guidance of ~$160-$170M. See why I rate PACB as a buy.

Esperion Therapeutics (ESPR): Q1 2022 Earnings Indicate 2021 Labors Paying Off In 2022 - Vimarsana News

Esperion Therapeutics (ESPR): Q1 2022 Earnings Indicate 2021 Labors Paying Off In 2022

Esperion Therapeutics reported their Q1 earnings that beat on EPS and revenue. It reported $13.4M in U.S. product revenue for Q1, which was up ~109% YoY. Click here to know why it's a Buy.